3D Recording of a Trans-rectal Prostate Biopsy
Recruitment status was Not yet recruiting
| Tracking Information | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First Received Date ICMJE | March 11, 2011 | ||||||||||||||||||||||||||||||||
| Last Updated Date | March 14, 2011 | ||||||||||||||||||||||||||||||||
| Start Date ICMJE | March 2011 | ||||||||||||||||||||||||||||||||
| Estimated Primary Completion Date | December 2011 (final data collection date for primary outcome measure) | ||||||||||||||||||||||||||||||||
| Current Primary Outcome Measures ICMJE |
Create 3D model of the prostate and accurately display the locations of the various biopsies taken during the procedure [ Time Frame: Post procedure ( off-line ) within a 3-5 working days ] [ Designated as safety issue: No ] | ||||||||||||||||||||||||||||||||
| Original Primary Outcome Measures ICMJE | Same as current | ||||||||||||||||||||||||||||||||
| Change History | Complete list of historical versions of study NCT01314456 on ClinicalTrials.gov Archive Site | ||||||||||||||||||||||||||||||||
| Current Secondary Outcome Measures ICMJE | Not Provided | ||||||||||||||||||||||||||||||||
| Original Secondary Outcome Measures ICMJE | Not Provided | ||||||||||||||||||||||||||||||||
| Current Other Outcome Measures ICMJE | Not Provided | ||||||||||||||||||||||||||||||||
| Original Other Outcome Measures ICMJE | Not Provided | ||||||||||||||||||||||||||||||||
| Descriptive Information | |||||||||||||||||||||||||||||||||
| Brief Title ICMJE | 3D Recording of a Trans-rectal Prostate Biopsy | ||||||||||||||||||||||||||||||||
| Official Title ICMJE | 3D Recording of a Trans-rectal Prostate Biopsy | ||||||||||||||||||||||||||||||||
| Brief Summary | Prostate biopsy is performed by multiple consecutive biopsy needle insertion into the prostate gland under a trans-rectal ultrasound probe guidance. Today, the performing physician navigates the needle using a momentary 2D ultrasound image (longitudinal and transverse B mode) without any record of the full prostate boundaries or previous biopsies' location. This study's Objectives are to record the trans-rectal biopsy procedure including the initial scan and the needle biopsy location and to modulate a 3D model of the prostate with accurate display the locations of the various biopsies taken during the procedure. |
||||||||||||||||||||||||||||||||
| Detailed Description | 3D record of a trans-rectal prostate biopsy Clinical Study Protocol Study no: NaviGo -01 Sponsor: UC-CARE. Apollo Bld. 3rd fl. Hi-Tech Park P.O.Box 67 Yokneam 20692 Israel Tel: 972-4-9097427 Fax:972-4-9937323 Feb. 2011 Version: 02 ABBREVIATIONS: 3D: 3 Dimensional 2D: 2 Dimensional TR: Trans-Rectal
Today, the performing physician navigates the needle using a momentary 2D ultrasound image (longitudinal and transverse B mode) without any record of the full prostate boundaries or previous biopsies' location. By recording the procedure the Navigo™ system will generate and display in off-line an accurate 3D model of the prostate and position the biopsies taken in the prostatic volume. 3. OBJECTIVES AND RATIONALE 3.1 Study objectives 1) To record the trans-rectal biopsy procedure including the initial scan and the needle biopsy location 2) To modulate a 3D model of the prostate and accurately display the locations of the various biopsies taken during the procedure 3.2 Rationale The Navigo™ system is a noninvasive system that allows the physician to accurately record the biopsy procedure without changing the imaging system, the biopsy routine or the techniques used today to scan and guide the biopsy needle insertion. The ability to create an accurate 3D model of the prostate and accurately position the biopsy needle location will allow the performing physician a more precise navigation and easier and more accurate biopsy within the prostate volume and enable a better analysis of the procedure and the pathological results, hence improved clinical outcomes with intended therapy or surveillance ( i.e.- prepare for follow-up biopsy procedure if needed). 4. DEVICE DESCRIPTION AND INTENDED USE The Navigo™ system is comprised of two main elements: a standard laptop computer with a digitizer input to record incoming video input (from the ultrasound system), and an electro-magnetic 3D tracking system. The 3D tracking system is connected via USB to the laptop computer, the transmitter is placed beneath the patient's mattress and two sensors are attached,- one to the ultrasound probe (at the base/ non invasive part of the probe) and the other to the patient's back. The Navigo™ system tracks and records the location of the ultrasound probe and the incoming video from the ultrasound system. The patient's movement is recorded and compensated when the ultrasound images are placed with reference to each other. In post procedure, the physician defines the boundaries of the prostate on selected ultrasound images and a 3D model of the prostate is displayed with all recorded biopsy specimens' locations displayed in the prostatic volume. The physician will be able to examine in post analysis the scattering quality of the biopsy specimens in the prostatic volume and update the pathology results. The 3D model can be rotated, manipulated and displayed in the physician's preferable choice. The Navigo™ system is intended to record and display in 3D the biopsy procedure of any patient undergoing a prostate trans-rectal biopsy. The Navigo™ system is intended to record all the data from the initial scan, the volume measurements, and the biopsy needle insertion. All the images are saved and can be reviewed in post analysis, the needle location can be updated according to the physician's marking on the recorded ultrasound image and the pathology results will be displayed in color on the 3D model. 5. METHODS AND PROCEDURES 5.1 Study Design The study is an open prospective study
5.2 Trial Procedure
6.2 Exclusion criteria
The Navigo system has been approved by the CE. The 3D tracking system is approved by the FDA for medical use and is classified as Type CF which is the most stringent classification, being required for those applications where the applied part is in direct conductive contact with the heart or other applications as considered necessary. The 3D tracking system is also part of an approved Helsinki trial in Bnei-zion hospital (monitoring of the birth progress, trial initiated by Dr. Yoav Paltieli) Adverse effects are not expected according to the accumulated experience with the 3D tracking system. Similarly, the Navigo™ system is not expected to add to the procedure any pain or discomfort to the patients. 9. SUBJECT RECUITMENT Study population will be recruited from the pool of patients who are scheduled for trans-rectal biopsy procedure 10. DATA ANALYSIS The data analysis will include the following steps: • Post procedure display of the prostate's 3D model and the location of the various biopsy specimens taken during the procedure in the prostatic volume • Comparison of the results with the physician analysis of the specimens location as derived from the images themselves 11. REFERENCE
|
||||||||||||||||||||||||||||||||
| Study Type ICMJE | Interventional | ||||||||||||||||||||||||||||||||
| Study Phase | Not Provided | ||||||||||||||||||||||||||||||||
| Study Design ICMJE | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Diagnostic |
||||||||||||||||||||||||||||||||
| Condition ICMJE |
|
||||||||||||||||||||||||||||||||
| Intervention ICMJE | Device: NaviGo
Video recording of a normal TRUS guided prostate biopsy with additional 2 , non invasive,electromagnetic sensors attached to the TRUS probe and the patient's back,- to allow for a 3D modeling of the prostate.
Other Name: 3D recording of a trans-rectal prostate biopsy |
||||||||||||||||||||||||||||||||
| Study Arm (s) | Experimental: NaviGo
Video recording of a normal TRUS guided prostate biopsy with additional 2 , non invasive,electromagnetic sensors attached to the TRUS probe and the patient's back,- to allow for a 3D modeling of the prostate.
Intervention: Device: NaviGo |
||||||||||||||||||||||||||||||||
| Publications * | Not Provided | ||||||||||||||||||||||||||||||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||||||||||||||||||||||||||
| Recruitment Information | |||||||||||||||||||||||||||||||||
| Recruitment Status ICMJE | Not yet recruiting | ||||||||||||||||||||||||||||||||
| Estimated Enrollment ICMJE | 50 | ||||||||||||||||||||||||||||||||
| Estimated Completion Date | December 2011 | ||||||||||||||||||||||||||||||||
| Estimated Primary Completion Date | December 2011 (final data collection date for primary outcome measure) | ||||||||||||||||||||||||||||||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||||||||||||||||||||||||||||
| Gender | Male | ||||||||||||||||||||||||||||||||
| Ages | 18 Years and older | ||||||||||||||||||||||||||||||||
| Accepts Healthy Volunteers | No | ||||||||||||||||||||||||||||||||
| Contacts ICMJE |
|
||||||||||||||||||||||||||||||||
| Location Countries ICMJE | Israel | ||||||||||||||||||||||||||||||||
| Administrative Information | |||||||||||||||||||||||||||||||||
| NCT Number ICMJE | NCT01314456 | ||||||||||||||||||||||||||||||||
| Other Study ID Numbers ICMJE | NaviGo- 01, 3D TRUS Bx recording | ||||||||||||||||||||||||||||||||
| Has Data Monitoring Committee | No | ||||||||||||||||||||||||||||||||
| Responsible Party | Michael Cohen, MD, Urology, HaEmek Medical center | ||||||||||||||||||||||||||||||||
| Study Sponsor ICMJE | HaEmek Medical Center, Israel | ||||||||||||||||||||||||||||||||
| Collaborators ICMJE |
|
||||||||||||||||||||||||||||||||
| Investigators ICMJE |
|
||||||||||||||||||||||||||||||||
| Information Provided By | HaEmek Medical Center, Israel | ||||||||||||||||||||||||||||||||
| Verification Date | March 2011 | ||||||||||||||||||||||||||||||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||||||||||||||||||||||||||||||